Global Trial in APG2575 for Patients With CLL/SLL
Trial details
- Registry ID
- NCT06104566
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Global Trial in APG2575 for Patients With CLL/SLLNCT06104566 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2026-12-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |